Awaiting development: Guidance and quality standards

Showing 301 to 310 of 394

Guidance and quality standards awaiting development
Title	Type
Serplulimab with chemotherapy for untreated PD-L1-positive unresectable advanced or recurrent oesophageal squamous cell cancer [TSID12411]	Technology appraisal guidance
Serplulimab with pemetrexed and carboplatin for untreated EGFR and ALK mutation-negative advanced non-squamous non-small-cell lung cancer [TSID12412]	Technology appraisal guidance
Setrusumab for treating osteogenesis imperfecta [ID6730]	Technology appraisal guidance
Sevabertinib for untreated HER2-positive advanced non-small-cell lung cancer [ID6616]	Technology appraisal guidance
Shared decision-making: practical guidance for health and social care professionals	Quality standard
Sibeprenlimab for treating IgA nephropathy [ID6604]	Technology appraisal guidance
Sigvotatug vedotin for Non-small-cell lung cancer [ID6718]	Technology appraisal guidance
Sleep disordered breathing	Quality standard
Social work interventions for adults with complex needs (including learning disabilities) and mental health needs	Quality standard
Somapacitan for treating growth failure associated with being small for gestational age, Noonan syndrome or idiopathic short height [ID6536]	Technology appraisal guidance